298 related articles for article (PubMed ID: 16278815)
21. Differential expression of the MAD2, BUB1 and HSP27 genes in Barrett's oesophagus-their association with aneuploidy and neoplastic progression.
Doak SH; Jenkins GJ; Parry EM; Griffiths AP; Baxter JN; Parry JM
Mutat Res; 2004 Mar; 547(1-2):133-44. PubMed ID: 15013707
[TBL] [Abstract][Full Text] [Related]
22. Promoter methylation profile in preneoplastic and neoplastic gallbladder lesions.
García P; Manterola C; Araya JC; Villaseca M; Guzmán P; Sanhueza A; Thomas M; Alvarez H; Roa JC
Mol Carcinog; 2009 Jan; 48(1):79-89. PubMed ID: 18543280
[TBL] [Abstract][Full Text] [Related]
23. p16 expression in Barrett's esophagus and esophageal adenocarcinoma: association with genetic and epigenetic alterations.
Hardie LJ; Darnton SJ; Wallis YL; Chauhan A; Hainaut P; Wild CP; Casson AG
Cancer Lett; 2005 Jan; 217(2):221-30. PubMed ID: 15617840
[TBL] [Abstract][Full Text] [Related]
24. Barrett's oesophagus--a pathologist's view.
Fléjou JF; Svrcek M
Histopathology; 2007 Jan; 50(1):3-14. PubMed ID: 17204017
[TBL] [Abstract][Full Text] [Related]
25. p16 inactivation by methylation of the CDKN2A promoter occurs early during neoplastic progression in Barrett's esophagus.
Bian YS; Osterheld MC; Fontolliet C; Bosman FT; Benhattar J
Gastroenterology; 2002 Apr; 122(4):1113-21. PubMed ID: 11910361
[TBL] [Abstract][Full Text] [Related]
26. p16(INK4a) lesions are common, early abnormalities that undergo clonal expansion in Barrett's metaplastic epithelium.
Wong DJ; Paulson TG; Prevo LJ; Galipeau PC; Longton G; Blount PL; Reid BJ
Cancer Res; 2001 Nov; 61(22):8284-9. PubMed ID: 11719461
[TBL] [Abstract][Full Text] [Related]
27. Epigenetic patterns in the progression of esophageal adenocarcinoma.
Eads CA; Lord RV; Wickramasinghe K; Long TI; Kurumboor SK; Bernstein L; Peters JH; DeMeester SR; DeMeester TR; Skinner KA; Laird PW
Cancer Res; 2001 Apr; 61(8):3410-8. PubMed ID: 11309301
[TBL] [Abstract][Full Text] [Related]
28. Similarity of aberrant DNA methylation in Barrett's esophagus and esophageal adenocarcinoma.
Smith E; De Young NJ; Pavey SJ; Hayward NK; Nancarrow DJ; Whiteman DC; Smithers BM; Ruszkiewicz AR; Clouston AD; Gotley DC; Devitt PG; Jamieson GG; Drew PA
Mol Cancer; 2008 Oct; 7():75. PubMed ID: 18831746
[TBL] [Abstract][Full Text] [Related]
29. Promoter hypermethylation of p16INK4a, E-cadherin, O6-MGMT, DAPK and FHIT in adenocarcinomas of the esophagus, esophagogastric junction and proximal stomach.
Schildhaus HU; Kröckel I; Lippert H; Malfertheiner P; Roessner A; Schneider-Stock R
Int J Oncol; 2005 Jun; 26(6):1493-500. PubMed ID: 15870861
[TBL] [Abstract][Full Text] [Related]
30. The molecular biology of esophageal adenocarcinoma.
Koppert LB; Wijnhoven BP; van Dekken H; Tilanus HW; Dinjens WN
J Surg Oncol; 2005 Dec; 92(3):169-90. PubMed ID: 16299787
[TBL] [Abstract][Full Text] [Related]
31. Prognostic value of p53 in Barrett's oesophagus.
Krishnadath KK; van Blankenstein M; Tilanus HW
Eur J Gastroenterol Hepatol; 1995 Jan; 7(1):81-4. PubMed ID: 7866817
[TBL] [Abstract][Full Text] [Related]
32. A quantitative promoter methylation profile of prostate cancer.
Jerónimo C; Henrique R; Hoque MO; Mambo E; Ribeiro FR; Varzim G; Oliveira J; Teixeira MR; Lopes C; Sidransky D
Clin Cancer Res; 2004 Dec; 10(24):8472-8. PubMed ID: 15623627
[TBL] [Abstract][Full Text] [Related]
33. Hypermethylation of the AKAP12 promoter is a biomarker of Barrett's-associated esophageal neoplastic progression.
Jin Z; Hamilton JP; Yang J; Mori Y; Olaru A; Sato F; Ito T; Kan T; Cheng Y; Paun B; David S; Beer DG; Agarwal R; Abraham JM; Meltzer SJ
Cancer Epidemiol Biomarkers Prev; 2008 Jan; 17(1):111-7. PubMed ID: 18199717
[TBL] [Abstract][Full Text] [Related]
34. Clonal analysis of a case of multifocal oesophageal (Barrett's) adenocarcinoma by comparative genomic hybridization.
van Dekken H; Vissers CJ; Tilanus HW; Tanke HJ; Rosenberg C
J Pathol; 1999 Jul; 188(3):263-6. PubMed ID: 10419593
[TBL] [Abstract][Full Text] [Related]
35. Activation of Akt is increased in the dysplasia-carcinoma sequence in Barrett's oesophagus and contributes to increased proliferation and inhibition of apoptosis: a histopathological and functional study.
Beales IL; Ogunwobi O; Cameron E; El-Amin K; Mutungi G; Wilkinson M
BMC Cancer; 2007 Jun; 7():97. PubMed ID: 17559672
[TBL] [Abstract][Full Text] [Related]
36. Surveillance in Barrett's oesophagus: will a strategy focused on a high-risk group reduce mortality from oesophageal adenocarcinoma?
Quera R; O'Sullivan K; Quigley EM
Endoscopy; 2006 Feb; 38(2):162-9. PubMed ID: 16479424
[TBL] [Abstract][Full Text] [Related]
37. Mutation analysis of the p53, APC, and p16 genes in the Barrett's oesophagus, dysplasia, and adenocarcinoma.
González MV; Artímez ML; Rodrigo L; López-Larrea C; Menéndez MJ; Alvarez V; Pérez R; Fresno MF; Pérez MJ; Sampedro A; Coto E
J Clin Pathol; 1997 Mar; 50(3):212-7. PubMed ID: 9155671
[TBL] [Abstract][Full Text] [Related]
38. [Risk stratification in medulloblastoma: screening for molecular markers].
Ebinger M; Senf L; Scheurlen W
Klin Padiatr; 2006; 218(3):139-42. PubMed ID: 16688669
[TBL] [Abstract][Full Text] [Related]
39. [Clinical significance of p53 tumor suppressor gene mutations in adenocarcinoma in Barrett esophagus].
Schneider PM; Hölscher AH; Wegerer S; König U; Becker K; Siewert JR
Langenbecks Arch Chir Suppl Kongressbd; 1998; 115(Suppl I):495-9. PubMed ID: 14518305
[TBL] [Abstract][Full Text] [Related]
40. Genetic diversity during the development of Barrett's oesophagus-associated adenocarcinoma: how, when and why?
Graham TA; McDonald SA
Biochem Soc Trans; 2010 Apr; 38(2):374-9. PubMed ID: 20298186
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
